止痛化癥胶囊联合注射用头孢他啶治疗慢性盆腔炎的效果

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (474 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the efficacy of Zhitong Huazheng Capsules combined with Ceftazidime for Injection in the treatment of chronic pelvic inflammatory disease. Methods A total of 100 patients with chronic pelvic inflammatory disease from Jinan Fourth People’s Hospital from February 2019 to October 2020 were selected. According to the random number table method, they were divided into control group and observation group, with 50 cases in each group. Control group received intravenous infusion of Ceftazidime for Injection, observation group was treated with Zhitong Huazheng Capsules on the basis of control group, both groups were treated for 14 days. The efficacy, pain, pelvic inflammatory mass diameter, high-sensitivity C-reactive protein (hs-CRP), human transforming growth factor receptor β1 (TGF-β1), malondialdehyde (MDA), superoxide dismutase (SOD), and the incidence of adverse reactions were compared between two groups. Results The total effective rate of observation group was higher than that of control group (P < 0.05). After 14 days of treatment, the levels of hs-CRP and MDA in two groups were lower than those before treatment, and observation group was lower than control group (P < 0.05); the levels of TGF-β1 and SOD in two groups were higher than those before treatment, and observation group were higher than control group (P < 0.05). After 14 days of treatment, visual analogue scale score in two groups were lower than those before treatment, and observation group was lower than control group (P < 0.05); the pelvic inflammatory mass diameter in two groups were smaller than those before treatment, and observation group was smaller than control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between two groups (P > 0.05). Conclusion Zhitong Huazheng Capsules combined with Ceftazidime for Injection in the treatment of chronic pelvic inflammatory disease can effectively reduce oxidative stress, reduce the level of inflammatory factors, improve clinical symptoms, it is safe and reliable.

Key words： Zhitong Huazheng Capsules Ceftazidime for Injection Chronic pelvic inflammatory disease Efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DONG Zhaoqin1 ZHANG Juan1 ZHANG Guilian2

Cite this article:

DONG Zhaoqin1 ZHANG Juan1 ZHANG Guilian2. Efficacy of Zhitong Huazheng Capsules combined with Ceftazidime for Injection in the treatment of chronic pelvic inflammatory disease[J]. 中国医药导报, 2021, 18(26): 85-89.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I26/85

[1] Curry A，Williams T，Penny ML. Pelvic Inflammatory Disease： Diagnosis，Management，and Prevention [J]. Am Fam Physician，2019，100（6）：357-364.
[2] Bugg CW，Taira T. Pelvic Inflammatory Disease： Diagnosis And Treatment In The Emergency Department [J]. Emerg Med Pract，2016，18（12）：1-24.
[3] 周江，毛莉.头孢他啶针联合奥硝唑片对慢性盆腔炎患者血管内皮功能及相关免疫因子的影响[J].中国妇幼保健，2020，35（13）：2376-2379.
[4] Shirley M. Ceftazidime-Avibactam：A Review in the Treatment of Serious Gram-Negative Bacterial Infections [J]. Drugs，2018，78（6）：675-692.
[5] 王涵，谭静，林红强，等.止痛化癥胶囊研究进展[J].内蒙古中医药，2019，38（1）：100-102.
[6] 周晴晴，王芳，李彦茹，等.止痛化癥片联合丹莪妇康煎膏对子宫内膜异位症术后CA125水平的影响[J].检验医学与临床，2019，16（6）：821-824.
[7] 乐杰.妇产科学[M].7版.北京：人民卫生出版社，2008.
[8] 郑筱萸.中药新药临床研究指导原则：试行[S].北京：中国医药科技出版社，2002：247-253.
[9] Chiarotto A，Maxwell LJ，Ostelo RW，et al. Measurement Properties of Visual Analogue Scale，Numeric Rating Scale，and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain： A Systematic Review [J]. J Pain，2019，20（3）：245-263.
[10] 孙雁群，赵瑞英，何松芝，等.基于代谢组学的慢性盆腔炎发病机制研究[J].中国妇幼保健，2018，33（7）：1610-1612.
[11] Cheng Y，Yuan Y，Jin Y，et al. Acupuncture for chronic pelvic inflammatory disease： A systematic review protocol [J]. Medicine（Baltimore），2018，97（13）：e0225.
[12] Graesslin O，Verdon R，Raimond E，et al. Management of tubo-ovarian abscesses and complicated pelvic inflammatory disease：CNGOF and SPILF Pelvic Inflammatory Diseases Guidelines [J]. Gynecol Obstet Fertil Senol，2019， 47（5）：431-441.
[13] 李雪芹，胡淑瑞，陈晓芳.宫炎康胶囊联合头孢他啶治疗慢性盆腔炎的临床研究[J].现代药物与临床，2020， 35（8）：1663-1666.
[14] Pogue JM，Bonomo RA，Kaye KS. Ceftazidime/Avibactam，Meropenem/Vaborbactam，or Both? Clinical and Formulary Considerations [J]. Clin Infect Dis，2019，68（3）：519-524.
[15] Sy SKB，Zhuang L，Sy S，et al. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination： A Model-Informed Strategy for its Clinical Development [J]. Clin Pharmacokinet，2019，58（5）：545-564.
[16] 周继红.中医辨证施护对慢性盆腔炎患者的临床疗效观察[J].长春中医药大学学报，2020，36（2）：164-166.
[17] 何静玲，郭清华，关玉兰.基于中医经络健康检测仪对盆腔炎性疾病后遗症慢性盆腔痛体质判断的研究[J].现代中西医结合杂志，2021，30（17）：1853-1856.
[18] 蔡怡园，赵淑萍.止痛化症胶囊对子宫内膜异位症患者血清CA125及VEGF的影响[J].山东医药，2009，49（21）：77-78.
[19] 卢土莲，戴海清，张艳丽.盆炎净Ⅰ号方治疗慢性盆腔炎的临床效果及对患者血清hs-CRP、IL-10、TGF-β1、PCT水平的影响[J]. 环球中医药，2018，11（2）：293-295.
[20] 王华斌.桂枝茯苓丸辅治慢性盆腔炎疗效及对血液流变学、氧化应激和血清hs-CRP、TGF-β1、GM-CSF、补体C3水平的影响[J].中华中医药学刊，2020，38（2）：214-217.
[21] 贺敏，郑蓉.当归芍药散联合三黄洗剂熏洗对慢性盆腔炎患者TGF-β1、IL-4及IL-10的影响[J].中国生化药物杂志，2016，36（4）：130-131，134.
[22] 谢萍，冯俭，杨张婧，等.清湿止痛汤对慢性盆腔炎大鼠血清IL-2和MDA水平影响的实验研究[J].河南中医，2011，31（6）：607-608.
[23] 沈正龙，刘虹，郑学刚.延黄妇炎清片对慢性盆腔炎大鼠血清中SOD、MDA影响的实验研究[J].新中医，2014， 46（10）：195-196.
[24] 崔媛，翟建军，冯碧波，等.磷霉素氨丁三醇散联合止痛化症胶囊治疗慢性盆腔炎的临床疗效研究[J].中国全科医学，2013，16（13）：1559-1561.
[25] 陈丽君，唐琛.穴位敷贴联合银甲丸、抗生素口服治疗湿热瘀结型慢性盆腔炎的临床效果[J].中国当代医药，2019，26（11）：164-167.
[26] 周敏，梅勰，周洁，等.止痛化症胶囊联合米非司酮治疗子宫腺肌症的Meta分析[J].云南中医中药杂志，2019， 40（11）：27-30.